{"id":5503,"date":"2026-06-08T21:00:25","date_gmt":"2026-06-08T21:00:25","guid":{"rendered":"https:\/\/digitalmarkettrends.com\/index.php\/2026\/06\/08\/tango-therapeutics-stock-soars-on-promising-pancreatic-cancer-data\/"},"modified":"2026-06-08T21:00:25","modified_gmt":"2026-06-08T21:00:25","slug":"tango-therapeutics-stock-soars-on-promising-pancreatic-cancer-data","status":"publish","type":"post","link":"https:\/\/digitalmarkettrends.com\/index.php\/2026\/06\/08\/tango-therapeutics-stock-soars-on-promising-pancreatic-cancer-data\/","title":{"rendered":"Tango Therapeutics stock soars on promising pancreatic cancer data"},"content":{"rendered":"
<\/div>\n

Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, vopimetostat.<\/p>\n

The drug was tested in combination with Revolution Medicines’ daraxonrasib.<\/p>\n

The sharp rally pushed the stock toward a record closing high and marked one of its strongest single-day performances in more than a year, as investors responded positively to data that suggested the drug combination could offer a promising new treatment option for pancreatic cancer, one of the deadliest forms of the disease.<\/p>\n

The latest results come from an ongoing Phase 1\/2 study evaluating vopimetostat alongside daraxonrasib and zoldonrasib in patients with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma, as well as non-small cell lung cancer.<\/p>\n

Pancreatic cancer data exceeds expectations<\/h2>\n

According to the company, the combination of vopimetostat and daraxonrasib produced a 92% objective response rate in pancreatic cancer patients, meaning tumors shrank or disappeared in 11 out of 12 evaluable participants.<\/p>\n

The study also showed a 90% progression-free survival rate after six months and 100% disease control, indicating that nearly all patients experienced either tumor reduction or disease stabilization.<\/p>\n

The combination demonstrated additional promise in a small group of non-small cell lung cancer patients, where the company reported a 100% response rate.<\/p>\n

A separate treatment arm combining vopimetostat with zoldonrasib generated a 52% objective response rate, a 74% six-month progression-free survival rate, and a 96% disease control rate in pancreatic cancer patients.<\/p>\n

Importantly, the company said the treatment combinations were generally well tolerated, with few major side effects reported and no treatment-related Grade 4 or Grade 5 adverse events observed.<\/p>\n

“The results from our ongoing combination trial dramatically exceeded our expectations,” Tango Therapeutics CEO Malte Peters said on a conference call Monday.<\/p>\n

Peters added that Tango’s “primary focus is now to bring forward” the vopimetostat and daraxonrasib combination “approach in pancreatic cancer.”<\/p>\n

The company said the findings support advancing the combination into a larger Phase 3 study as a potential first-line, chemotherapy-free treatment for newly diagnosed pancreatic cancer patients by the end of 2026.<\/p>\n

Analysts turn more optimistic<\/h2>\n

Wall Street analysts responded positively to the data, with several firms raising price targets and reiterating bullish ratings.<\/p>\n

Wolfe Research upgraded Tango Therapeutics to “Outperform” from “Peer Perform” and assigned a $35 price target. Analyst Kalpit Patel described the findings as “groundbreaking with no major red flags.”<\/p>\n

The firm also increased its estimate for vopimetostat’s unadjusted global peak sales potential to approximately $2.6 billion from $1.9 billion while raising its probability of success.<\/p>\n

Mizuho analyst Joseph Catanzaro also maintained an “Outperform” rating and increased his price target to $36 from $30.<\/p>\n

Catanzaro said the data “starts to tell a potentially very compelling signal of improved long-term outcomes.”<\/p>\n

B. Riley Securities analyst Yuan Zhi also raised his price target to $35 from $21 while maintaining a Buy rating.<\/p>\n

Zhi described the 92% objective response rate from the vopimetostat and daraxonrasib combination as “unprecedented.”<\/p>\n

He added that the early results leave Tango Therapeutics “undervalued at current levels.”<\/p>\n

Focus shifts to late-stage development<\/h2>\n

While the study remains relatively small and does not include a comparison group, Monday’s update adds to growing industry enthusiasm surrounding daraxonrasib and the broader effort to improve outcomes for pancreatic cancer patients.<\/p>\n

Tango also highlighted additional pipeline opportunities, with Peters noting that future data releases involving vopimetostat as a standalone treatment in lung cancer and its TNG456 therapy in glioblastoma represent “significant long-term opportunity” for the company.<\/p>\n

The latest findings have strengthened investor confidence that vopimetostat could evolve into a late-stage pancreatic cancer program, particularly as the company prepares for larger clinical trials.<\/p>\n

Overall, analysts appear broadly optimistic about Tango’s prospects. <\/p>\n

According to FactSet data cited in reports, the company currently carries an average Buy rating among Wall Street firms, with an average price target of approximately $35.09.<\/p>\n

As the company moves toward Phase 3 testing, investors will be watching closely to see whether the promising early data can be replicated in larger studies.<\/p>\n

The post Tango Therapeutics stock soars on promising pancreatic cancer data<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, vopimetostat. The drug was tested in combination with Revolution Medicines’ daraxonrasib. The sharp rally pushed the stock toward a record closing high and marked one of its strongest single-day […]<\/p>\n","protected":false},"author":1,"featured_media":5504,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-5503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/posts\/5503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/comments?post=5503"}],"version-history":[{"count":0,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/posts\/5503\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/media\/5504"}],"wp:attachment":[{"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/media?parent=5503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/categories?post=5503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digitalmarkettrends.com\/index.php\/wp-json\/wp\/v2\/tags?post=5503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}